VIVUS partially redeemed itself to shareholders yesterday after releasing impressive prescription data for its obesity drug Qsymia -- but it'll take more than that for this drug to reach blockbuster status. To make matters worse, the Belviq launch by VIVUS' rival Arena Pharmaceuticals is just around the corner and could put a wet towel on VIVUS' recent progress if it proves to be successful.

However, the battle for dominance in the obesity space is just getting started. Focusing on VIVUS in this video, health care analyst Max Macaluso identifies three areas that the company rapidly needs to improve if it hopes to dominate this therapeutic space.


What's inside Supernova?
If you're an investor looking for big long term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

The article 3 Ingredients for an Obesity Drug Blockbuster originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Introduction to ETFs

The basics of Exchange Traded Funds and why ETFs are hot.

View Course »

Investing in Real Estate

Learn the basics of investing in real estate.

View Course »

Add a Comment

*0 / 3000 Character Maximum